Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant

NCT02396134 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT02396134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02396134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
May 21, 2015
Completion date
September 19, 2024
Enrollment
61 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase chronic myelogenous leukemia, bcr-abl1 positive, adult acute lymphoblastic leukemia in remission, adult acute myeloid leukemia in remission, adult hodgkin lymphoma, adult lymphoblastic lymphoma, adult non-hodgkin lymphoma, chronic lymphocytic leukemia, chronic phase chronic myelogenous leukemia, bcr-abl1 positive, cytomegaloviral infection, hematopoietic and lymphoid cell neoplasm, hla-a*0201 positive cells present, myelodysplastic syndrome, myelofibrosis, myeloproliferative neoplasm